Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

Global Markets News

In a market where noise often overshadows substance, Nuvectis Pharma (NASDAQ:NVCT)* is delivering a signal that’s hard to ignore — sustained insider buying by one of the company’s most informed and sophisticated investors. On June 20, 2025, Charles Mosseri-Marlio, a well-known biotech investor and former pharmaceutical executive, filed a Form 4 disclosing the purchase of 33,442 additional shares of NVCT at $8.05 per share. The $270,000 transaction adds to his already significant position, which now totals just under 3 million shares through Emerald Hill Capital. This marks the third major insider buy by Mosseri-Marlio in 2025 alone — with previous purchases in February and May at lower price points. The pattern is clear: this is not opportunistic trading, it’s strategic accumulation. What makes this even more notable is Mosseri-Marlio’s background. He previously held a leadership role at Flamel Technologies (now Avadel Pharmaceuticals), where he helped secure development deals with top-tier partners like Pfizer and GlaxoSmithKline. He’s not only familiar with drug pipelines — he’s built them. Combined with a track record in institutional asset management, his buying carries more weight than your average insider move. He’s not chasing momentum — he’s betting on execution. And there’s plenty in the Nuvectis pipeline to justify that bet. The company is currently advancing two first-in-class oncology candidates — NXP800 and NXP900 — both of which are in clinical trials targeting cancers with high unmet need. NXP800 is in Phase 1b development for ARID1a-mutated, platinum-resistant ovarian cancer — a devastating subtype with few effective treatments. The drug has already earned Fast Track and Orphan Drug designations from the FDA, streamlining its development and signaling strong regulatory support. Data from this trial is expected later this year, and could be a key near-term catalyst. NXP900, meanwhile, is designed to address drug resistance in advanced cancers, including non-small cell lung cancer. By inhibiting SRC and YES1 kinases, NXP900 targets the very mechanisms that allow tumors to escape the effects of EGFR and ALK inhibitors — two of the most common first-line treatments in NSCLC. After completing its Phase 1a study, the company is now preparing to launch combination trials that could demonstrate its potential to restore drug sensitivity in resistant tumors. Despite these promising programs, Nuvectis remains deeply undervalued relative to peers. The company’s market cap sits around $150 million — a fraction of other precision oncology players at similar stages. Nuvalent (NASDAQ: NUVL), for example, trades north of $6 billion with programs focused on the same indication space. Summit Therapeutics (NASDAQ: SMMT), which also targets drug-resistant cancers, surged to nearly $15 billion in valuation earlier this year following a pivotal trial result. Nuvectis isn’t there yet — but if it delivers on either of its two clinical programs, it may not be far behind. Importantly, the company is financially stable. Nuvectis raised $15.5 million in early 2025, bringing its total cash reserves to nearly $30 million as of March. That provides runway into 2027, giving it ample time to reach key milestones without returning to the market for funding. It also means less dilution risk — a crucial factor for investors in early-stage biotech. This backdrop of strong insider ownership, solid financials, and high-impact drug development is what makes the Mosseri-Marlio buying spree so compelling. He’s not the only one with conviction either — CEO Ron Bentsur and other insiders continue to hold sizable stakes and have not sold a single share. Bentsur, notably, has a track record of taking biotech companies through FDA approval and delivering real value to shareholders. Year-to-date, NVCT is up significantly but it’s still relatively under the radar. That may not last long. With clinical data expected soon, strong internal alignment, and one of the most experienced insider buyers in the sector continuing to build his position, Nuvectis Pharma may be one of the few small-cap biotechs positioned for a breakout in the second half of 2025. - News Highlights from Nuvectis Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting - * Paid Advertisement Disclaimer & Disclosure: This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. This article was Published by the. Wall Street Wire™ platform and network, which is operated by Arx Advisory Ltd (the “Operators”). The Operators receive a monthly cash subscription fee from Nuvectis Pharma (NVCT) via bank transfer for services relating to promotional content and news distributions on various media and social channels. The Operators may received additional cash fees for monitoring, data or IR/advisory services on top of that. For specific details and full disclosures on the exact cash amounts paid for the Wall Street Wire subscription and the start date of such services, please refer to our full disclosure document: https://redditwire.com/terms Contact Details News Coverage media.globalmarkets@gmail.com

June 20, 2025 11:56 AM Eastern Daylight Time

With Fresh Funding and Strong Phase 3 Data, PolyPid Advances Towards FDA Approval

Global Markets News

PolyPid Ltd. (NASDAQ: PYPD) * announced Tuesday that it has secured $26.7 million through warrant exercises following its successful SHIELD II Phase 3 trial results. This funding milestone extends the company’s runway beyond the anticipated FDA approval of its breakthrough surgical infection prevention technology, D-PLEX₁₀₀. For savvy biotech investors seeking undervalued opportunities with near-term catalysts, PolyPid presents a compelling case study in market inefficiency and potential outsized returns. A David Taking On a $10 Billion Goliath Surgical site infections (SSIs) represent a massive burden on healthcare systems, costing hospitals tens of thousands of dollars per incident while significantly increasing patient mortality. The $10 billion SSI prevention market has long awaited innovation beyond traditional antibiotic approaches. Enter PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) platform, which delivers targeted antibiotics directly at surgical sites for a full 30 days—dramatically longer than conventional methods that typically provide only hours of protection. “D-PLEX₁₀₀ demonstrated a statistically significant reduction in surgical site infections and successfully met the study’s primary endpoint and all key secondary endpoints,” the company stated in its announcement of the Phase 3 SHIELD II trial results. Most impressively, in patients with large surgical incisions, earlier SHIELD I data showed a remarkable 54% reduction (p=0.0032) in the composite endpoint of infections, reinterventions, and mortality compared to standard of care alone. The more recent SHIELD II trial demonstrated an even more stunning 58% reduction in surgical site infections, dropping infection rates from 9.5% with standard care to just 3.8% when D-PLEX100 was added. Why This $36M Company Could Soon Command a Valuation in the Hundreds of Millions Despite delivering transformative clinical results, PolyPid currently trades around $3.53 per share (as of June 18, 2025), representing a market cap of approximately $36 million – a significant discount to comparable companies in the surgical and pain management sectors, many of which command valuations in the hundreds of millions to over $1 billion. This valuation disconnect creates a potential opportunity for investors ahead of multiple catalysts: 1. NDA Submission in Early 2026: The company expects to file its New Drug Application in early 2026, leveraging Fast Track and Breakthrough Therapy designations already granted by the FDA. 2. Medicare’s New Technology Add-On Payment Eligibility: D-PLEX₁₀₀ qualifies for this program, potentially providing up to 75% reimbursement during early commercialization years. 3. U.S. Partnership Discussions: Management noted during a recent call that there has been “a change in partnering interest following December’s interim analysis,” with large pharmaceutical and medical device companies representing logical partners. 4. Substantial Market Opportunity: With 12 million eligible surgeries annually in the U.S. alone and another 8 million in Europe, D-PLEX₁₀₀’s market potential is substantial. 5. European Partnership Already Secured: PolyPid has secured a European commercialization partnership with Advanz Pharma worth up to $115 million plus double-digit royalties. The newly secured $26.7 million adds to PolyPid’s existing capital resources. With this additional funding, the company has stated that its runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀. Beyond D-PLEX₁₀₀: Platform Technology Offers Additional Growth Potential While D-PLEX₁₀₀ drives immediate value creation, PolyPid’s broader PLEX platform provides significant growth opportunities beyond surgical infections. Their OncoPLEX program applies identical technology principles to deliver cancer therapeutics directly to tumor sites, potentially revolutionizing solid tumor treatment approaches. A recent collaboration with ImmunoGenesis validates the platform’s broader applications beyond surgical infections. According to recent analyst reports, Wall Street remains bullish on PolyPid. H.C. Wainwright recently raised their price target to $13 (from $11), while analysts from JMP Securities and Craig-Hallum have maintained Buy ratings. On June 5, 2025, Roth MKM initiated coverage with a Buy rating. The consensus among Wall Street professionals points to price targets ranging from $10-13, suggesting significant upside potential from current levels. The Bottom Line For investors seeking opportunities with clear catalysts, PolyPid represents a compelling combination of transformative clinical results, definitive regulatory pathway, and strong Wall Street support. With clinical risk substantially reduced following successful Phase 3 results and a regulatory submission timeline now established, the focus shifts to commercial execution and partnership value creation—potentially setting the stage for significant share price appreciation as these milestones materialize. The company’s notable discount to peers, extended cash runway, and multiple near-term value drivers make it an intriguing opportunity for biotech investors looking for undervalued assets with clear paths to value creation. Recent News Highlights from PolyPid PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints This article is syndicated from The Finance Herald. * Paid Advertisement Disclaimer & Disclosure: This article was Published by Wall Street Wire™. Wall Street Wire™ is owned and operated by Arx Advisory Ltd (the “Operator”). The Operator receives an ongoing monthly subscription fee of $5,000 cash via bank transfer (since May 1st, 2025 which is ongoing as of the date of publication) from PolyPid Ltd (PYPD) (IL0011326795) to produce and distribute this content and additional promotional content and news distributions on various media and social channels. The operator receives additional cash fees for non promotional data and consulting subscriptions from PolyPid. This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. Please refer to our full disclosure and disclaimer here: https://redditwire.com/terms. Contact Details Wall Street Wire media.globalmarkets@gmail.com

June 18, 2025 11:22 AM Eastern Daylight Time

News Release

LezDo TechMed Launches Seamless Medical Record Review Billing Through CaseDrive

LezDo TechMed

LezDo TechMed Launches Seamless Medical Record Review Billing Through CaseDrive New York, NY, United States, 18th Jun 2025 - LezDo TechMed, one of the leading medical record review outsourcing firms in the U.S, has officially launched its next-generation medical record review billing system through their product CaseDrive. With the launch of this one-of-a-kind tool, the company promises to deliver a seamless, transparent, and intelligent billing experience tailored for their clientele including IMEs, QMEs, law firms, insurance firms, and life care planners. Recognizing the persistent challenges surrounding the billing in outsourced medical record review services like hidden fees to confusing invoices and delayed payments, LezDo TechMed has introduced this cutting-edge solution designed to eliminate hassles and elevate client trust. At the focus of this innovation lies CaseDrive, the company’s AI-powered medical record platform that brings real-time billing visibility and automated invoicing for clients. “With this launch, we’re are happy to address one of the biggest pain points of our clients in the medical record review industry,” said a spokesperson for LezDo TechMed. “Our ultimate goal is to offer clients complete transparency, financial control, and ultimately peace of mind while trust us for their medical record review services like narrative summaries, medical chronologies, deposition summaries, APS summaries etc.” Advanced Features Now Live with CaseDrive Flexible Billing Cycles No more pressure on billing cycles! With CaseDrive, clients can choose a suitable billing cycle that aligns with their internal accounting process flow. Whether they prefer weekly, monthly or per case payments, LezDo TechMed ensures accurate, timely, and transparent invoicing with clearly itemized service breakdowns. Tailored Billing Packages From small firms to enterprise clients, the firm supports every client with tailored billing packages as per the criteria like case volume, turnaround time, and complexity, thereby maximizing cost efficiency without compromising service quality. Specialized Billing Summaries Billing summaries is another highlight that not only help clients understand what they’re paying for but also support in their audit preparation and financial documentation compliance with industry standards. CaseDrive is another promising launch by the firm, understanding the pain points the clients often face when it comes to outsourcing record review services. With this sophisticated innovation by LezDoTechMed, billing and payment in medical record review outsourcing had turned out to be a hassle-free journey for the clients. About LezDo TechMed LezDo TechMed is a renowned medical record review outsourcing company offering high-quality medical data analysis across the U.S. With its AI-powered medical data analysis and client-first approach, the firm stands out, leading innovation in medical record reviews and billing automation. Contact Details LezDo TechMed Robert Smith sales@lezdotechmed.com Company Website https://www.lezdotechmed.com/

June 18, 2025 10:50 AM Eastern Daylight Time

News Release

LezDo TechMed Launches Seamless Medical Record Review Billing Through CaseDrive

LezDo TechMed

LezDo TechMed, one of the leading medical record review outsourcing firms in the U.S, has officially launched its next-generation medical record review billing system through their product CaseDrive. With the launch of this one-of-a-kind tool, the company promises to deliver a seamless, transparent, and intelligent billing experience tailored for their clientele including IMEs, QMEs, law firms, insurance firms, and life care planners. Recognizing the persistent challenges surrounding the billing in outsourced medical record review services like hidden fees to confusing invoices and delayed payments, LezDo TechMed has introduced this cutting-edge solution designed to eliminate hassles and elevate client trust. At the focus of this innovation lies CaseDrive, the company’s AI-powered medical record platform that brings real-time billing visibility and automated invoicing for clients. “With this launch, we’re are happy to address one of the biggest pain points of our clients in the medical record review industry,” said a spokesperson for LezDo TechMed. “Our ultimate goal is to offer clients complete transparency, financial control, and ultimately peace of mind while trust us for their medical record review services like narrative summaries, medical chronologies, deposition summaries, APS summaries etc.” Advanced Features Now Live with CaseDrive Flexible Billing Cycles No more pressure on billing cycles! With CaseDrive, clients can choose a suitable billing cycle that aligns with their internal accounting process flow. Whether they prefer weekly, monthly or per case payments, LezDo TechMed ensures accurate, timely, and transparent invoicing with clearly itemized service breakdowns. Tailored Billing Packages From small firms to enterprise clients, the firm supports every client with tailored billing packages as per the criteria like case volume, turnaround time, and complexity, thereby maximizing cost efficiency without compromising service quality. Specialized Billing Summaries Billing summaries is another highlight that not only help clients understand what they’re paying for but also support in their audit preparation and financial documentation compliance with industry standards. CaseDrive is another promising launch by the firm, understanding the pain points the clients often face when it comes to outsourcing record review services. With this sophisticated innovation by LezDoTechMed, billing and payment in medical record review outsourcing had turned out to be a hassle-free journey for the clients. About LezDo TechMed LezDo TechMed is a renowned medical record review outsourcing company offering high-quality medical data analysis across the U.S. With its AI-powered medical data analysis and client-first approach, the firm stands out, leading innovation in medical record reviews and billing automation. Contact Details LezDo TechMed Robert Smith sales@lezdotechmed.com Company Website https://www.lezdotechmed.com/

June 18, 2025 10:30 AM Eastern Daylight Time

CURE ALZHEIMER’S FUND PRESENTS THE JEFFREY L. MORBY PRIZE FOR EXCEPTIONAL RESEARCH

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease (AD), has announced the recipients of the second annual Jeffrey L. Morby Prize. Senior author Andrew S. Yoo, Ph.D., and first author Zhao Sun, Ph.D., both of Washington University School of Medicine in St. Louis, were selected by their peers for their paper “ Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming,” published in Science in August 2024. The Morby Prize is named in honor of the late Co-Founder of Cure Alzheimer’s Fund, Jeffrey L. Morby, who inspired the nonprofit’s mission 20 years ago to fund research as a path to ending Alzheimer’s disease. Mr. Morby passed away in September 2023. Established in 2024, the Morby Prize will be awarded annually to the senior and first authors of a recent scientific publication that transforms the fundamental understanding of Alzheimer’s disease and opens new paths to translate scientific results into effective ways to prevent, diagnose or treat the disease. This year’s award included $200,000 for the senior author’s lab for Alzheimer’s disease-related research. “Honoring researchers whose work is determined by their peers as breakthrough thinking and having meaningful impact on the Alzheimer’s community is a fitting tribute to Jeff’s remarkable legacy of empowering scientists to pursue rigorous and innovative research,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “The many extraordinary CureAlz-funded projects that resulted in published papers in 2023 and 2024 made the competition for this award fierce, and the endorsement of this paper by their peers speaks to the importance of the work of Drs. Yoo and Sun and their co-authors.” The paper describes a groundbreaking method to study aged neurons in the lab without requiring a brain biopsy, enabling more accurate modeling of late-onset Alzheimer’s disease. By transforming skin cells from patients directly into neurons that reflect the aging process, scientists now can observe key disease features, such as amyloid beta plaque buildup, offering new insights into Alzheimer’s disease development and potential treatment approaches. “With the demonstration that direct neuronal reprogramming can model neuropathological features of late-onset Alzheimer’s disease, this method will enable us to dissect how aging, as the primary risk factor, contributes to neurodegeneration,” said Dr. Yoo. “Moreover, the generous support from the Jeffrey L. Morby Prize will further allow us to develop reprogramming approaches to generate different neuronal subtypes and investigate neuron-intrinsic aging mechanisms in the context of specific cell types. We are excited about the possibility of delineating the mechanisms by which different neuronal subtypes become vulnerable or resilient to AD with aging.” About The Yoo Lab Andrew S. Yoo, Ph.D., is a distinguished neuroscientist and professor in the Department of Developmental Biology at Washington University School of Medicine in St. Louis. His lab focuses on microRNAs as neurogenic genetic inputs and reprogramming effectors to generate human neurons by directly reprogramming non-neural somatic cells. Using this approach, his team investigates how aging in human neurons contributes to the adult- and late-onset of neurodegeneration employing neurons derived from individuals with various neurodegenerative disorders. About Cure Alzheimer's Fund Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided 971 grants to more than 300 of the world’s leading researchers and contributed more than $232 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has achieved a 100% perfect score and a Four-Star rating for 13 consecutive years from Charity Navigator. Cure Alzheimer’s Fund also received a Platinum Seal of Transparency from Candid, formerly known as GuideStar. Our Board of Directors, Trustees and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website http://curealz.org

June 18, 2025 05:25 AM Eastern Daylight Time

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says

Global Markets News

BiomX Inc. (NYSE: PHGE)* has achieved what Big Pharma couldn't accomplish in over 20 years — successful clinical trials using viruses to treat life-threatening infections that no longer respond to antibiotics. The $10 million biotech has reported positive Phase 2 results in diabetic foot bone infections, a condition so challenging that no new drugs have been approved for it in two decades. Meanwhile, their cystic fibrosis program showed 14% of patients completely cleared chronic lung infections after just 10 days of treatment. Approximately 160,000 lower limb amputations occur annually in diabetic patients in the U.S., with 85% caused by diabetic foot infections or diabetic foot osteomyelitis — creating an $8 billion annual healthcare burden according to company data. Current treatments rely on antibiotics that increasingly fail due to resistance, often leaving amputation as the only option. Clinical Breakthroughs Across Two Major Programs BiomX's March 2025 Phase 2 results in diabetic foot osteomyelitis from 41 patients delivered notable outcomes. The company achieved statistically significant percent area reduction of ulcer size, with p-values of 0.046 at week 12 and 0.052 at week 13. The treatment showed separation from placebo starting at week 7, with differences greater than 40% by week 10. BiomX also demonstrated statistically significant improvements in ulcer depth and reducing ulcer area expansion, while BX211 was safe and well-tolerated throughout the study. The company's cystic fibrosis program has been equally impressive. In their Phase 1b/2a study, 14.3% of patients converted to sputum culture negative for P. aeruginosa after 10 days of treatment, compared to 0% in the placebo group. One patient had been infected for 35 years before achieving complete clearance. The FDA has granted this program both Fast Track designation and Orphan Drug Designation, potentially accelerating the approval pathway. BiomX's approach uses bacteriophages — viruses that naturally target and kill specific bacteria — instead of traditional antibiotics that bacteria can develop resistance against. The company has overseen more than 50 compassionate use cases with no significant side effects to date. Military Validation and Wall Street's Bullish Take The U.S. Defense Health Agency has provided $40 million in non-dilutive funding to BiomX's diabetic foot program, representing significant validation of the technology. "They're seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections," CEO Jonathan Solomon said during the company's May 2025 earnings call. Despite the clinical progress and military backing, BiomX trades at approximately $10 million market cap — a disconnect0 that has caught Wall Street's attention. H.C. Wainwright maintains a Buy rating with a $15 price target, representing potential upside of over 3000% from recent levels around $0.4 Laidlaw & Company rates the stock Buy with a $16 price target, suggesting almost 4000% upside potential. Laidlaw analyst Yale Jen called the recent data "an absolutely positive surprise" and characterized BX211 as "a high value and clinically de-risked asset." The analysts' optimism stems from the clinical validation across both programs, massive addressable markets, and limited competition in the phage therapy space. Major Catalysts on the Horizon BiomX estimates addressable markets exceeding $2.5 billion globally for their diabetic foot program and $1.6 billion for cystic fibrosis based on patient populations and potential pricing benchmarks. The company expects to have sufficient funding through Q1 2026, aligning with anticipated BX004 Phase 2b results in cystic fibrosis. Key upcoming catalysts include the Phase 2b readout for their cystic fibrosis program expected in Q1 2026, ongoing Phase 2/3 trial discussions with the FDA for their diabetic foot program, and potential regulatory meetings in the second half of 2025. The company is also exploring partnership opportunities as the phage therapy space attracts increasing attention from large pharmaceutical companies. With validated clinical data, military funding, and Wall Street price targets suggesting potential returns exceeding 3000%, BiomX could offer investors exposure to phage therapy as a potential new approach to treating antibiotic-resistant infections. As the global antibiotic resistance crisis intensifies, the company's nature-based approach to killing bacteria positions it at an interesting inflection point in infectious disease treatment. BiomX shares were trading at ~$0.4 at last check Recent News Highlights from BiomX BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) * Legal Disclaimer & Disclosure: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Wall Street Wire™. The operators of Wall Street Wire, arx advisory, are not registered brokers, dealers, or investment advisers. This report contains and is a form of paid promotional content or advertisement for BiomX Inc and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by BiomX Inc prior to publication. The operators of wall street wire have received or are expected to receive a monthly recurring fee of five thousand united states dollars via wire transfer from BiomX as part of an ongoing agreement starting June 1st, 2025 in return for social media distribution and promotional coverage services, and receive additional compensation for non promotional unrelated data and advisory services on top of that. They do not hold any shares in BiomX. Please review the full disclaimers and compensation disclosures here for further details: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we endorse them, they are quoted based on publicly available news reports believed to be reliable and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details News Coverage ronald@futuremarketsresearch.com

June 16, 2025 07:04 PM Eastern Daylight Time

Sheon Karol Joins West Lane Partners as Senior Advisor

West Lane Partners

West Lane Partners, a private equity firm focused on special situations in middle market companies spanning healthcare, tech, financial services and industrials, is pleased to announce that Sheon Karol, a nationally recognized investment banker and restructuring advisor, has joined the firm as a Senior Advisor. Mr. Karol brings over three decades of experience in investment banking, restructuring, and senior corporate leadership, with deep expertise in complex M&A, capital raises, and operational turnarounds. Skilled in de-risking situations, he brings a flexible yet disciplined approach that favors iterative decision-making over rigid or binary choices. His ability to surface a range of strategic options, often under pressure, has made him a trusted advisor to owners navigating both opportunity and uncertainty. His contributions to the field have earned national recognition, including the “Boutique Investment Banker of the Year” award from the Atlas Awards. “Sheon and I have been in the trenches together on complex deals. He’s masterful at aligning stakeholders, cutting through noise, and adapting in real time to keep transactions on course. Where others see roadblocks, he sees possibility—and responds with clarity and flexibility,” said Deryck Palmer, Founder and Managing Partner at West Lane Partners. “His dynamic approach, experience, and deep market insight into the industries on which we’re focused, and an instinct for what owners value most, makes him an exceptional addition to our firm.” “I think of the middle market as the river less fished” said Mr. Karol. “Middle market companies are often overlooked, undercapitalized, and underserved by institutional talent. At West Lane Partners, our focus on investments between $25 million and $75 million is about more than deal size—it’s about bringing high-caliber insight to businesses at pivotal moments and tailoring strategic options to match the evolving goals of owners and the realities of the market. The result is not just getting deals done, but generating long-term value others might miss.” Mr. Palmer added, “I’ve always been impressed by Sheon’s expertise, creativity, positivity and determination to get the best for his clients. These qualities enable him to inexorably bring difficult situations to their best possible conclusion and there are few who bring such capabilities to the middle market.” About Sheon Karol Mr. Karol has advised on high-stakes transactions across a myriad of industries in the middle market, including manufacturing, biotech, pharma, for-profit education, medical research, agriculture, consumer goods, food & grocery, sports, and technology. Mr. Karol has successfully executed a wide range of strategic transactions, including M&A advisory, capital raises, and restructurings, for both healthy and distressed businesses and their stakeholders. He has also served in executive capacities, including as Chief Restructuring Officer of a $1 billion company, for which he renegotiated the company's debt and avoided a bankruptcy filing. Many of Mr. Karol’s transactions, including Violin Memory and Peekay Boutiques, have won awards. He served as SVP of Winn-Dixie and managed the company's sale of assets in excess of $200 million and the disposition of 326 stores (in a 90-day period); guided the auction and sale of Farmland’s nitrogen fertilizer business that exceeded the “stalking horse” bid by $25 million; advised the CRO in the sale of the Texas Rangers baseball team; and advised foreign buyers in their U.S. expansion. Trustee positions include the Violin Memory and Lily Robotics Trusts. A middle market M&A thought leader, he writes and lectures widely, including on entrepreneurship, auction theory, sale processes, the middle market and foreign buyers. He holds FINRA SIE, Series 63 and Series 79 certifications. Mr. Karol received a J.D. from Yale Law School and a B.A. from Yeshiva College. About West Lane Partners West Lane Partners is a private equity firm whose senior leadership has over 150 years of collective restructuring and private equity experience working with underperforming, stressed and distressed companies across a range of industries in both large cap and middle market companies. In addition to providing capital, the firm combines decades of restructuring, private equity, legal and financial expertise to collaborate with management in developing and executing bespoke solutions that deliver mutually beneficial outcomes. Contact Details Curtis Johnson, Investor Relations +1 973-404-0999 cjohnson@westlanepartners.com Meir Kahtan Public Relations, LLC Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.westlanepartners.com

June 11, 2025 10:00 AM Eastern Daylight Time

Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market

Medicus Pharma Ltd (MDCX)

The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine. These twin forces, rising demand fueled by aging and disease prevalence along with technological innovation, are propelling unprecedented growth across biopharma markets. The global biotechnology sector is projected to expand from $1.74 trillion in 2025 to over $5 trillion by 2034, representing a compound annual growth rate (CAGR) of 12.5 percent. Specialty pharmaceuticals, including biologics and novel drug delivery systems, are expected to grow even faster, with forecasts predicting a 26.5 percent CAGR over the same period. Oncology remains a key driver, with spending on cancer medicines forecasted to nearly double from $252 billion in 2024 to $441 billion by 2029. Meanwhile, veterinary oncology is emerging as a high-potential frontier, with the U.S. market alone projected to reach $1.48 billion by 2030, driven by rising pet ownership and demand for advanced care. The urology therapeutics segment also shows steady growth potential, expected to rise from $10.5 billion in 2024 to $15.8 billion by 2033. Amid this expansive and interconnected landscape, Medicus Pharma Ltd. (NASDAQ: MDCX) is methodically positioning itself to capitalize on these powerful market tailwinds. Through a diversified portfolio of innovative drug delivery platforms and targeted therapies, Medicus addresses some of the most pressing health challenges across human and veterinary medicine. Medicus Pharma: Methodically Building a High-Leverage Growth Story Though still flying under many investors’ radars, Medicus Pharma is rapidly assembling the elements of a high-leverage growth story. On June 2, the company completed a $7 million public offering, selling 2,260,000 units at $3.10 each. Each unit includes one common share plus one warrant exercisable at the same price over five years. The capital will primarily fund a Phase 2 proof-of-concept trial in basal cell carcinoma (BCC) using Medicus’s flagship doxorubicin-loaded dissolvable microneedle patch (D-MNA). Additional funds may support broader development in non-melanoma skin cancers or other pipeline programs. Strategic Veterinary Expansion: FDA Submission for Equine Squamous Cell Carcinoma This timely financing was quickly followed by a major regulatory milestone. On June 9, Medicus announced submission of a formal product development plan to the U.S. FDA for a veterinary application of D-MNA targeting equine squamous cell carcinoma (SCC). The program is advancing under an Investigational New Animal Drug (INAD) file, aiming for conditional approval. It leverages the same microneedle patch technology used in human dermatologic trials, demonstrating a strategic effort to repurpose clinical data and technology across human and veterinary markets. Tapping an Untapped Veterinary Oncology Opportunity The equine indication represents a significant market opportunity. As CEO Dr. Raza Bokhari highlighted, “In veterinary medicine, where only a handful of oncology drugs are approved, developing a non-invasive treatment for equine SCC targets a largely unmet need, a potential $250 million market.” The planned study will enroll 50 horses across five U.S. sites in a placebo-controlled design, comparing two D-MNA doses against placebo, with tumor response assessed at day 90. Medicus has secured FDA Minor Use in Major Species (MUMS) Designation, which grants seven years of market exclusivity upon approval, a valuable commercial advantage in a segment with limited competition. D-MNA Platform: Promising Safety and Efficacy Data The D-MNA patch, originally developed for human skin cancers, is supported by encouraging early data. A Phase 1 trial in Australia (SKNJCT-001) involving 13 patients with nodular BCC showed the treatment was well tolerated with no dose-limiting toxicities. Remarkably, 46 percent of lesions achieved complete histological clearance after a single application, an impressive result given the minimally invasive delivery. This platform delivers doxorubicin directly into the dermis through a biodegradable microneedle array, minimizing systemic exposure while concentrating the drug’s effect at the tumor site. Expanding Clinical Trials Across Continents Building on this foundation, Medicus is running two Phase 2 trials. In the U.S., the SKNJCT-003 study recently expanded enrollment from 60 to 90 patients following a positive interim analysis that showed over 60 percent clinical clearance. This multicenter, placebo-controlled trial compares the patch to the standard of care, with European sites now joining due to growing investigator interest. Concurrently, the SKNJCT-004 trial in the United Arab Emirates involves 36 patients across four hospitals, including Cleveland Clinic Abu Dhabi, targeting both histological and clinical clearance endpoints. Strategic Acquisition: Entering Late-Stage Urology Complementing its internal pipeline, Medicus is also positioning itself as a consolidator of high-value assets. In April, the company signed a binding letter of intent to acquire UK-based Antev Ltd., whose lead candidate, Teverelix, is a GnRH antagonist in late-stage development for two urology indications: acute urinary retention (AUR) due to benign prostatic hyperplasia and hormone-sensitive prostate cancer in patients at elevated cardiovascular risk. These combined markets represent a $6 billion annual opportunity, and Teverelix has completed multiple clinical trials in Europe. Under the deal, Antev shareholders would receive approximately 19 percent of Medicus’s post-merger equity, plus up to $65 million in milestone payments tied to regulatory and commercial successes. A Platform With Multiple Growth Levers Together, Medicus offers optionality and platform leverage across human oncology, veterinary medicine, and dermatology, all fields marked by limited innovation and strong pricing power. Its lead asset is already in Phase 2 with international trial sites and active FDA engagement. The veterinary program offers a faster commercialization path with fewer regulatory barriers, while the Antev acquisition could propel Medicus into late-stage, multi-billion-dollar indications. Why Investors Should Watch MDCX Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory filing. Clinical trials across humans and animals are expanding, and a transformative acquisition is imminent. With a methodical approach tying together clinical progress, intellectual property, and market strategy, Medicus is quietly building momentum, making MDCX a stock to watch closely in the second half of 2025. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 10, 2025 10:20 AM Eastern Daylight Time

HPS and PayMedix Partner with Gravie to Expand Access and Simplify Healthcare Payments

PayMedix

MILWAUKEE, WI – June 10, 2025 – PayMedix, a leading healthcare financing and payments solution, and HPS, one of Wisconsin’s largest independent provider networks, today announced a strategic partnership with Gravie, a health benefits company reimagining health plans for small and midsize businesses. As a result of this partnership, eligible Gravie members will gain access to the comprehensive HPS provider network and benefit from the transparency and ease of the PayMedix payment platform. The collaboration reflects a shared commitment between Gravie, HPS, and PayMedix to help reshape the healthcare experience with solutions that prioritize improved access and member well-being. "This partnership represents a fundamental shift in how regional employers can approach healthcare benefits," said Brian Marsella, President of HPS and PayMedix. "Gravie's mission to make health benefit plans work for everyone is well-aligned with our vision to make healthcare more affordable and accessible for all. By combining Gravie's level-funded approach with our comprehensive network and payment solutions, we're creating new possibilities for employers to transition from traditional fully-insured arrangements to more flexible, cost-effective plan designs." Through this partnership, eligible Gravie members will gain access to HPS's Wisconsin provider network, which includes over: 100 hospitals 30,000 physicians 1,200 clinics 630 behavioral health providers Members will also benefit from PayMedix, a healthcare payment experience that simplifies the billing process. PayMedix pays contracted providers in full and consolidates all medical billing into one clear, monthly statement, the SuperEOB ®, which displays all charges, insurance payments, and patient balances into a single view. To make healthcare even more accessible for everyone, PayMedix offers interest-free financing and flexible repayment plans to all members for all allowed in-network expenses up to their out-of-pocket maximum, with no credit check required, removing a common barrier to care and delivering financial peace of mind. "At Gravie, we're constantly seeking innovative ways to improve our members' healthcare experience," said Evan Peters, SVP of Networks at Gravie. "Partnering with HPS and PayMedix allows us to offer greater access to high-quality regional care while removing financial barriers that too often prevent people from getting the care they need. This partnership represents another exciting step toward making healthcare work better for Wisconsin families." ___________________________________ About Health Payment Systems (HPS) HPS is a privately held healthcare technology and services organization with solutions that reduce the cost and complexity of the healthcare payments process to benefit providers, employers, patients, and TPAs. Headquartered in Milwaukee, Wisconsin, HPS has an independent network of 100+ hospital facilities and 30,000+ individual providers. About PayMedix PayMedix is the only company solving the problem of high out-of-pocket costs for everyone –providers, employers, patients, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and interest-free financing for all patients. PayMedix has processed over $6 billion in medical payments for hospital systems and physician practices and can overlay any provider network. About Gravie Gravie is the only health benefits company bringing both level-funded and ICHRA health plans to small and midsize employers. Comfort ®, Gravie’s flagship product, is the nation’s first-of-its-kind health plan that provides first-dollar, no-cost coverage on most common healthcare services, at a cost comparable to traditional group health plans. Contact Details Hattie Ninteau hninteau@hps.md Company Website https://paymedix.com

June 10, 2025 10:00 AM Eastern Daylight Time

1 2 3 4 5 ... 306